These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26344419)

  • 1. Olaparib.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2016 Jan; 81(1):171-3. PubMed ID: 26344419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib for the treatment of ovarian cancer.
    Bornstein E; Jimeno A
    Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R; Gourley C
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
    Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract]   [Full Text] [Related]  

  • 12. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib for the treatment of breast cancer.
    Griguolo G; Dieci MV; Guarneri V; Conte P
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib.
    Bochum S; Berger S; Martens UM
    Recent Results Cancer Res; 2018; 211():217-233. PubMed ID: 30069770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS; Eskander RN; Monk BJ
    Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.